Anti-Aging Peptide Stacks: A Canadian Research Guide

Why anti-aging stacks require their own category#

The search term "anti-aging peptide stacks Canada" usually arrives at Northern Compound after a researcher has already read individual guides to Epitalon, NAD+, or SS-31, and now wants to know whether combining those compounds produces research outcomes beyond what each compound achieves alone. That question is legitimate. It is also easy to overstate.

Most of the evidence for individual anti-aging peptides in the Canadian research landscape is preclinical, often cell-line or rodent based, and sometimes jurisdiction-specific. When those same compounds are studied in combination, the evidence thins further. There are no published Phase 1 trials of Epitalon plus NAD+ in humans. There are no randomised controlled trials of SS-31 plus NAD+. The combination rationale rests on mechanistic inference from single-compound studies, plus a small but growing body of cell-culture work that examines co-exposure rather than true multi-compound in vivo protocols.

This guide is designed to prevent two common errors. The first is assuming that because two peptides target "aging," they must work better together. The second is assuming that because the evidence is thin, no combination is worth studying. The reality is more nuanced: some pairs have orthogonal mechanisms that justify a testable interaction hypothesis, while others overlap so heavily that their combination adds little epistemic value but substantially increases analytical cost.

Northern Compound treats all peptides discussed here as research-use-only materials. This guide is not medical advice, not a dosing protocol, not an anti-aging regimen, and not a recommendation for personal or cosmetic use. Canadian researchers should operate within the framework of the Food and Drugs Act, institutional ethics approval, and biosafety standards.

The mechanistic landscape: four pillars of peptide longevity research#

Before evaluating specific combinations, it is worth mapping the four mechanistic categories that define the current anti-aging peptide literature. Each category represents a different cellular system, a different biomarker set, and a different experimental design.

Telomere and clock-gene maintenance#

This category is dominated by Epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide originally developed at the St. Petersburg Institute of Gerontology. Epitalon's primary research associations are with the pineal gland, melatonin secretion rhythms, and telomerase enzyme expression. In vitro studies report that Epitalon can upregulate hTERT mRNA and extend telomere length in human fibroblasts and lymphocytes (PMC12411320). Animal studies describe restored circadian rhythmicity and extended lifespan in senescence-accelerated mouse strains.

The mechanistic model is that Epitalon acts on the pineal transcriptional programme, influencing the expression of genes involved in circadian regulation and cell-cycle control. Whether that influence translates into genuine telomere lengthening in terminally differentiated tissues, or whether the effect is confined to proliferative cell cultures, remains an active question. The evidence is strongest in cell lines, moderate in rodents, and extremely limited in humans.

Mitochondrial bioenergetics and oxidative stress#

SS-31 (elamipretide, D-Arg-dimethylTyr-Lys-Phe-NH₂) is a mitochondria-targeted tetrapeptide that accumulates in the inner mitochondrial membrane by electrophoretic attraction to the large negative membrane potential. Its primary mechanism involves binding to cardiolipin, a phospholipid essential for the structural organisation and functional efficiency of respiratory complexes I, III, and IV. By stabilising cardiolipin, SS-31 preserves electron-transport chain integrity and reduces reactive oxygen species leakage under oxidative stress conditions (PMC6588449).

SS-31 is the most clinically advanced peptide in the anti-aging category. It has received regulatory attention for rare mitochondrial diseases and for conditions involving acute ischemia-reperfusion injury. That clinical maturity does not make it an "anti-aging drug" in the cosmetic or wellness sense, but it does mean that the pharmacokinetic and safety profile is better characterised than for most research peptides.

Sirtuin signalling and NAD⁺ metabolism#

NAD+ (nicotinamide adenine dinucleotide) is not a peptide, but it is the central cofactor for sirtuin deacetylases and a substrate for PARP DNA-repair enzymes. Declining NAD⁺ levels with age have been documented across multiple species and tissues, and the decline is associated with reduced mitochondrial function, impaired DNA repair, and altered metabolic flexibility (PMC4112140).

Supplementation with NAD⁺ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — has been studied in human trials for effects on muscle mitochondria, cardiovascular function, and insulin sensitivity. The evidence is mixed: some trials report modest improvements in NAD⁺-related biomarkers, while others find no significant clinical benefit beyond the preclinical stage. For Canadian peptide researchers, the interest in NAD⁺ is not as a peptide itself but as a metabolic node that peptide-based tools such as SS-31 or Epitalon might intersect.

Metabolic-senescence and energy sensing#

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial 12S rRNA region. It activates AMP-activated protein kinase (AMPK) and modulates cellular energy sensing, glucose uptake, and fatty acid oxidation. Research models describe MOTS-c as improving insulin sensitivity, reducing metabolic inflammation, and protecting against diet-induced obesity in rodents. Its relevance to anti-aging research lies in the AMPK-mTOR-senescence axis: AMPK activation suppresses mTOR signalling, which in turn influences cellular senescence entry and the senescence-associated secretory phenotype (SASP).

Why the four categories matter for stack design#

A stack that combines two peptides from the same category risks additive receptor occupancy without mechanistic insight. A stack that combines peptides from different categories has a stronger rationale, because it asks whether two independent cellular systems can be modulated simultaneously to produce a research outcome that neither system produces alone. The question is not "more is better." The question is "do these two pathways interact in a way that produces a measurable, interpretable effect?"

The Epitalon + NAD⁺ combination#

Mechanistic rationale#

The most frequently discussed anti-aging stack in Canadian research communities pairs Epitalon with NAD⁺. The rationale rests on pathway orthogonality. Epitalon is associated with telomerase upregulation, pineal circadian-gene expression, and possibly melatonin-axis modulation. NAD⁺ is associated with sirtuin activity, mitochondrial biogenesis, PARP-mediated DNA repair, and metabolic redox balance. These are not the same pathway. They do not share a receptor. They do not compete for the same intracellular pool.

The hypothesised synergy is temporal and genomic. If Epitalon genuinely extends cellular replicative lifespan by preserving telomere integrity, the cells undergoing that extension must still maintain their metabolic machinery, repair oxidative damage, and regulate energy balance. NAD⁺-mediated sirtuin activity is central to all three. A cell with longer telomeres but failing mitochondria is not meaningfully "younger." Conversely, a cell with robust NAD⁺/sirtuin signalling but critically shortened telomeres will enter replicative senescence regardless. The combination hypothesis, then, is that simultaneous support for both telomere maintenance and metabolic maintenance might outperform either intervention alone in models that track both endpoints.

What the individual literature says#

The Epitalon literature is concentrated in Russian and Eastern European journals, with a smaller but growing presence in Western cell-biology and gerontology publications. Key findings include:

• Telomerase upregulation: In human somatic cell lines, Epitalon exposure increased telomerase activity and extended population doublings before senescence (PMC12411320).
• Circadian restoration: In senescence-accelerated mice, Epitalon restored pineal melatonin rhythmicity and extended median lifespan compared with control groups.
• Gene-expression changes: Microarray studies report epigenetic modifications in genes related to cell proliferation, apoptosis, and immune regulation following Epitalon administration.

The NAD⁺ literature is larger and more international. Key findings relevant to combination research include:

• Sirtuin activation: NAD⁺ is the obligate substrate for sirtuins 1 through 7, which regulate DNA repair, mitochondrial biogenesis, inflammation, and metabolic enzyme activity.
• Mitochondrial maintenance: In rodent models, NAD⁺ precursor supplementation improved mitochondrial respiratory capacity in muscle and brain tissue, particularly under conditions of metabolic stress or age-related decline.
• PARP competition: NAD⁺ is also consumed by PARP enzymes during DNA damage response. Under conditions of high DNA damage, PARP activity can deplete the NAD⁺ pool available for sirtuins, creating a tension between repair and maintenance functions.

What the combination literature says#

Direct studies of Epitalon plus NAD⁺ are sparse. Cell-culture co-exposure experiments have been reported in conference abstracts and non-peer-reviewed sources, but systematic, independent, peer-reviewed combination studies are not yet available. The absence of data does not invalidate the rationale, but it does mean that any Canadian researcher designing a combination protocol is operating in exploratory territory.

A defensible combination study would need to define endpoints that capture both the telomere/pineal dimension and the metabolic/mitochondrial dimension. Suitable endpoints might include:

• telomere length by quantitative PCR or flow-FISH in proliferating cells.
• telomerase activity by TRAP assay.
• NAD⁺/NADH ratio by enzymatic cycling assay or mass spectrometry.
• sirtuin activity (SIRT1, SIRT3) by fluorometric substrate assay or Western blot.
• mitochondrial membrane potential by JC-1 or TMRE fluorescence.
• metabolic flux (oxygen consumption rate, extracellular acidification rate) by Seahorse analyser.
• senescence-associated β-galactosidase staining as an integrated ageing marker.

Without at least three of these endpoints, a combination study risks producing uninterpretable data. A study that only measures cell viability, for example, cannot distinguish telomere-mediated survival from metabolic rescue.

The SS-31 + NAD⁺ combination#

Mechanistic rationale#

If Epitalon plus NAD⁺ is the telomere-metabolism stack, SS-31 plus NAD⁺ is the mitochondria-only stack with a narrow, deep focus. SS-31 acts on the inner mitochondrial membrane by binding cardiolipin and preserving the structural integrity of respiratory complexes. NAD⁺ acts upstream by providing the substrate for sirtuin-mediated mitochondrial biogenesis and mitophagy regulation. Together, they address two different phases of mitochondrial maintenance: SS-31 preserves existing mitochondrial infrastructure, while NAD⁺ supports the creation of new mitochondria and the clearance of damaged ones.

The rationale is stronger than for many peptide combinations because the individual compounds have more clinical and preclinical data than most research peptides. SS-31 has been studied in human heart-failure trials. NAD⁺ precursors have been studied in human metabolic and muscle-function trials. That maturity means the researcher is not building on single cell-line papers alone.

What the individual literature says#

SS-31 has been studied extensively in cardiac, renal, neurodegenerative, and muscular models. Key findings include:

• Cardiac protection: In a randomised placebo-controlled trial, SS-31 improved peak VO₂ and reduced symptoms in patients with heart failure with preserved ejection fraction, though the effect was modest and the trial was not powered for hard endpoints.
• Renal protection: In preclinical models, SS-31 preserved glomerular filtration rate and reduced tubular injury in diabetic nephropathy and ischemia-reperfusion settings.
• Neuroprotection: In rodent models of Parkinson's disease and traumatic brain injury, SS-31 reduced oxidative damage and improved mitochondrial respiration in affected brain regions.

NAD⁺ precursor research has produced mixed but instructive results:

• Muscle mitochondrial function: In a randomised trial of older men, nicotinamide riboside increased muscle NAD⁺ content and improved markers of mitochondrial biogenesis, though functional outcomes did not always reach significance.
• Cardiovascular outcomes: Some trials reported modest improvements in systolic blood pressure and arterial stiffness with NAD⁺ precursor supplementation, while others found no effect.
• Cognitive and neurological models: Rodent studies describe neuroprotective effects of NAD⁺ precursors in models of Alzheimer's disease, ischemic stroke, and traumatic brain injury, though human translation remains uncertain.

What the combination literature says#

Published combination studies of SS-31 and NAD⁺ are limited. One preclinical model examined the combination in a renal ischemia-reperfusion setting and reported additive protection compared with either compound alone, but the study was small, used surrogate endpoints, and has not been independently replicated. Another conference abstract described co-administration in a cardiac pressure-overload model, again reporting additive effects on mitochondrial respiration and oxidative stress markers.

For a Canadian researcher, these signals are promising but preliminary. A well-designed combination study might use a rodent model of ageing (senescence-accelerated mice, naturally aged rats) with endpoints that specifically track mitochondrial ultrastructure (electron microscopy), respiratory function (Seahorse or Oroboros respirometry), NAD⁺ pool size, and tissue-level oxidative damage (4-HNE, protein carbonyls). The study should include vehicle, SS-31 alone, NAD⁺ precursor alone, and the combination, with adequate power to detect interactions.

The SS-31 + Epitalon combination#

Is there a rationale?#

The pairing of SS-31 with Epitalon is less discussed than either peptide with NAD⁺, but it is not without logic. Epitalon's clock-gene and telomere effects occur in the nucleus and at the level of transcriptional regulation. SS-31's effects occur in mitochondria. The two compartments communicate: mitochondrial ROS influence nuclear NF-κB signalling, and NAD⁺ flux shuttles between compartments via the malate-aspartate shuttle and other transporters. A combination that stabilises both nuclear telomere maintenance and mitochondrial bioenergetics might produce integrated cellular resilience that a single-compound protocol does not.

However, the combination is more speculative than SS-31 + NAD⁺ or Epitalon + NAD⁺ because there is no shared metabolic intermediate. Epitalon does not obviously increase NAD⁺ synthesis. SS-31 does not obviously influence telomerase expression. The researcher who designs an SS-31 plus Epitalon study is testing a more distal interaction hypothesis: that cellular ageing is a systems-level phenomenon requiring simultaneous maintenance at multiple subcellular locations.

That hypothesis is intellectually appealing but experimentally demanding. A study would need endpoints in both nucleus and mitochondrion, temporal tracking to see whether effects emerge at different rates, and a clear definition of what "integrated cellular resilience" means in measurable terms.

The MOTS-c addition: energy sensing and senescence#

MOTS-c occupies a different niche from the other anti-aging peptides. It is not a telomere regulator and not a direct mitochondrial membrane stabiliser. It is an energy-sensing peptide that activates AMPK and thereby suppresses mTOR signalling. In ageing biology, mTOR suppression is associated with extended lifespan across multiple species, from yeast to mice. The mechanism is thought to involve reduced protein synthesis, enhanced autophagy, and delayed entry into cellular senescence.

Adding MOTS-c to an anti-aging stack introduces a nutrient-sensing dimension that the other compounds do not directly address. A researcher might hypothesise that MOTS-c-mediated AMPK activation would enhance the mitochondrial quality-control effects of SS-31 or the metabolic maintenance effects of NAD⁺, by increasing mitophagy and reducing the accumulation of damaged organelles. Alternatively, MOTS-c might interact with Epitalon by altering the metabolic state of proliferating cells, thereby influencing how telomere maintenance translates into functional lifespan extension.

The evidence for MOTS-c in combination protocols is almost entirely theoretical. Single-compound studies in rodents describe improved insulin sensitivity, reduced adiposity, and better exercise capacity. Those effects are consistent with AMPK activation but do not tell us how MOTS-c would behave in a multi-compound setting. A Canadian researcher interested in this combination should design a pilot study with explicit AMPK and mTOR endpoints, not just lifespan or general healthspan metrics.

What "synergy" means in anti-aging peptide research#

The word "synergy" is used casually in peptide forums but has a precise meaning in pharmacology. Two compounds are synergistic when their combined effect exceeds the sum of their individual effects at comparable concentrations. That definition requires three conditions:

1. Quantifiable effects: Each compound must produce a dose-dependent change in a specific endpoint.
2. Additivity model: The researcher must define what "sum of individual effects" means mathematically. Common models include Bliss independence (for effects on probabilities) and Loewe additivity (for dose-response curves).
3. Statistical test: The observed combination effect must be compared against the predicted additive effect with appropriate statistical power and correction for multiple comparisons.

Most anecdotal reports of "synergy" in anti-aging peptide stacks fail all three conditions. They describe subjective improvements, use uncontrolled single-subject designs, and do not distinguish interaction effects from placebo, regression to the mean, or lifestyle confounders. For research purposes, synergy is a hypothesis to be tested, not a claim to be assumed.

In the specific context of anti-aging peptides, synergy testing is even harder because the endpoints are longitudinal. Telomere lengthening, mitochondrial biogenesis, and lifespan extension take weeks to months to measure in rodents, and years in humans. A researcher who wants to test synergy between Epitalon and NAD⁺ in a rodent model needs a study length of at least several months, a large sample size to detect modest effect differences, and endpoints that capture both pathways independently. That level of investment is rarely made for exploratory hypotheses, which is one reason the published combination literature is so thin.

Comparison table: anti-aging stack combinations#

This table summarises the landscape but does not replace protocol design. The "research risk level" reflects epistemic risk — the probability of producing uninterpretable or misleading data — rather than safety risk in the clinical sense.

Study design principles for anti-aging peptide stacks#

Define the biological system first#

A common mistake in anti-aging research is to choose compounds before defining the model. The correct order is: identify the cellular system that is most relevant to the research question (telomeres, mitochondria, senescence, metabolic sensing), choose the endpoint that best captures that system, and then select the compound or combination that most directly modulates the pathway leading to that endpoint.

If the research question is "Does combination X extend replicative lifespan in human fibroblasts?" the endpoint is population doublings, and the relevant compounds are Epitalon and possibly NAD⁺. If the question is "Does combination Y improve mitochondrial respiratory capacity in aged skeletal muscle?" the endpoint is oxygen consumption rate per milligram of tissue, and the relevant compounds are SS-31 and NAD⁺.

A study that does not define the system and endpoint before selecting compounds is likely to produce noise. Anti-aging is not a single endpoint. It is a family of related but distinct phenomena, and different peptides address different members of that family.

Use factorial designs for combination testing#

The minimum standard for combination research is a 2×2 factorial design: vehicle control, compound A alone, compound B alone, and A plus B. This design allows the researcher to estimate main effects (the independent contribution of each compound), interaction effects (whether the presence of one compound alters the effect of the other), and synergy or antagonism (whether the combined effect deviates from additivity).

Sample-size calculations for factorial designs should be powered for the interaction term, not just the main effects. Interaction effects are typically smaller than main effects and require larger samples to detect. A researcher who powers only for main effects will often miss a genuine interaction or will report a spurious interaction in an underpowered study.

Pre-registration of the analysis plan is particularly valuable for longevity research because the timelines are long and the temptation to change endpoints or analysis methods mid-study is strong. Pre-registration locks the protocol before data collection begins and makes post-hoc changes transparent.

Choose endpoints that match mechanism#

For Epitalon-plus-NAD⁺ studies, endpoints should include:

• Telomere length by qPCR or flow-FISH.
• Telomerase activity by TRAP assay.
• NAD⁺/NADH ratio.
• SIRT1 and SIRT3 protein levels or activity.
• Mitochondrial membrane potential.
• Senescence-associated β-galactosidase.
• Cell-cycle distribution by flow cytometry.

For SS-31-plus-NAD⁺ studies, endpoints should include:

• Oxygen consumption rate (OCR) and spare respiratory capacity.
• Mitochondrial membrane potential by TMRE.
• Cardiolipin content by LC-MS.
• Reactive oxygen species (ROS) production by MitoSOX or Amplex Red.
• ATP/ADP ratio.
• NAD⁺ pool size and NAD⁺/NADH ratio.
• Mitochondrial DNA copy number.

A study that measures only one or two endpoints cannot distinguish pathway-specific effects from general cellular stress responses.

Control for batch, storage, and analytical variation#

Anti-aging peptides are often expensive and sourced from multiple suppliers. Batch-to-batch variation in purity, fill amount, and degradation products can easily swamp small biological effects. The researcher should:

• Use a single lot for each peptide throughout the study, or stratify the analysis by lot if multiple lots are unavoidable.
• Store lyophilised peptides at -20°C or below, desiccated, and protected from light.
• Reconstitute immediately before use, and avoid freeze-thaw cycles.
• Verify peptide identity and purity by independent third-party analysis if the supplier COA is more than six months old.
• Include vehicle controls that match the pH, osmolality, and excipient composition of the peptide preparations.

Document everything for reproducibility#

Longevity studies are expensive and time-consuming. The only way to make them cumulative is to document every variable that could influence the outcome. The research record should include:

• Supplier name, lot number, and date of receipt for each peptide.
• Storage conditions and temperature logs.
• Reconstitution date, solvent, pH, and concentration.
• Animal strain, age, sex, housing conditions, and diet.
• Randomisation method, blinding protocol, and statistical analysis plan.
• Raw data files, not just summary statistics.

Analytical standards for combination sourcing#

Independent verification for each peptide#

When a researcher orders two peptides for a combination study, each peptide should have its own lot-matched certificate of analysis. A single COA that covers multiple products is inadequate. The COA should include:

• Sequence identity confirmation by mass spectrometry.
• Purity by HPLC with peak integration and area percent.
• Fill amount or concentration.
• Appearance and physical description.
• Storage conditions and expiration date.
• Research-use-only statement.

The blend problem#

Some suppliers offer pre-mixed anti-aging peptide blends. These products are convenient but analytically hazardous. A single vial containing Epitalon and NAD⁺ precursor may not resolve both compounds cleanly on HPLC, because their molecular weights, charge profiles, and retention times differ substantially. Mass spectrometry may ionise one compound more efficiently than the other, producing misleading ratios.

For research purposes, independent vials are preferable. They allow separate identity confirmation, independent reconstitution, and precise control over the ratio. If a pre-mixed blend is the only option, the researcher should request independent analytical data for each component, or should have the blend independently assayed before use.

Canadian shipping and importation#

Research-use-only peptides are not scheduled controlled substances in Canada, but importation requires accurate declaration and research-purpose documentation. A multi-compound order may attract greater customs scrutiny than a single-compound order. Researchers should:

• Use clear, accurate customs declarations ("research peptides," "analytical standards," not "supplements" or "vitamins").
• Include a printed copy of the research protocol or institutional affiliation letter.
• Request cold-chain shipping with temperature logging for temperature-sensitive compounds.
• Verify that the supplier provides tracking and insurance for international shipments.

The Canadian researcher's guide to buying research peptides covers importation and sourcing standards in more detail.

What the evidence does not say#

It is important to be explicit about the limits of the current literature, because search intent around "anti-aging peptide stacks" often carries an implicit assumption that combinations are proven to work.

There are no published randomised controlled trials of Epitalon plus NAD⁺ in humans. There are no published combination studies of SS-31 plus NAD⁺ that meet Western clinical-trial standards. There are no published combination studies of Epitalon plus SS-31. There are no published combination studies involving MOTS-c with any other anti-aging peptide. The entire combination rationale is built on mechanistic inference, cell-culture co-exposure data, and anecdotal reports.

That does not mean the combinations are ineffective. It means the question has not been adequately tested. A researcher who approaches anti-aging stacks with appropriate scepticism, rigorous endpoint selection, and factorial experimental design can make a genuine contribution to the field. A researcher who assumes synergy and skips validation will simply add noise.

Northern Compound does not endorse specific stacks, dosages, or protocols. We provide analytical and contextual information to support researcher decision-making. All compounds discussed are research-use-only materials unless supplied through a lawful therapeutic pathway.

FAQ: Anti-aging peptide stack research#

References and further reading#

• Khavinson VKh, et al. "Epitalon increases telomere length in human cell lines through telomerase upregulation." Biogerontology (PMC12411320)
• Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends Cell Biol (PMC4112140)
• Dai D-F, et al. "Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice." Aging Cell (PMC6588449)
• Lu H, et al. "MOTS-c: A mitochondrial-derived peptide in the regulation of metabolism and aging." Ageing Res Rev (2020)
• Northern Compound: Best Anti-Aging Peptides Canada
• Northern Compound: Epitalon vs NAD+
• Northern Compound: Epitalon Canada Guide
• Northern Compound: NAD+ Canada Guide
• Northern Compound: SS-31 Canada Guide
• Northern Compound: MOTS-c Canada Guide

Conclusion: stacks are a research frontier, not a product category#

The search term "anti-aging peptide stacks Canada" compresses a sprawling research frontier into five words. What lies behind that term is not a catalogue of validated combinations but a set of mechanistic hypotheses that remain largely untested. The strongest hypothesis, supported by orthogonal pathways and moderate individual evidence, is the pairing of Epitalon with NAD⁺ for simultaneous telomere and metabolic maintenance. The next strongest is SS-31 with NAD⁺ for integrated mitochondrial preservation and biogenesis. The MOTS-c addition introduces a metabolic-sensing dimension that is theoretically interesting but empirically thin.

For Canadian researchers, the practical message is that combination anti-aging research demands more analytical rigour, not less. Independent identity confirmation, factorial experimental design, mechanism-driven endpoint selection, and rigorous documentation are not optional extras. They are the minimum standards required to produce data that can be interpreted honestly and built upon by future studies.

The supplier landscape matters as well. Not all peptide vendors are willing to provide the level of documentation required for serious combination research. Pre-mixed blends without independent component purity data, COAs that lack lot numbers, and products marketed with therapeutic claims should all be treated as inappropriate for research use. The analytical risk of a poorly characterised combination far exceeds the convenience of a pre-mixed vial.

Northern Compound will continue to monitor the peer-reviewed literature for published combination studies and will update this guide as new data emerge. Until then, we encourage researchers to approach anti-aging stacks as experimental hypotheses rather than proven protocols, and to maintain the same scepticism and analytical discipline that they would apply to any other unexplored pharmacological interaction. The only way to find out whether these combinations are genuinely useful is to study them properly — with clear hypotheses, appropriate controls, and the humility to publish null and negative findings alongside positive ones.